210 related articles for article (PubMed ID: 32980845)
1. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary.
Abdel-Rahman O
Neuroendocrinology; 2021; 111(9):876-882. PubMed ID: 32980845
[TBL] [Abstract][Full Text] [Related]
2. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Nondigestive, Nonpulmonary Primary.
Abdel-Rahman O; Ghosh S
Pancreas; 2022 Aug; 51(7):769-773. PubMed ID: 36395402
[TBL] [Abstract][Full Text] [Related]
3. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study.
Abdel-Rahman O; Pham TM; Pokhrel A; Ruether D; Sawyer MB
Am J Clin Oncol; 2022 May; 45(5):208-214. PubMed ID: 35383575
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms.
Abdel-Rahman O; Ghosh S
Am J Clin Oncol; 2022 Aug; 45(8):338-343. PubMed ID: 35696696
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
[TBL] [Abstract][Full Text] [Related]
7. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
9. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms.
Abdel-Rahman O; Ghosh S; Morrish D
J Endocrinol Invest; 2022 Sep; 45(9):1683-1688. PubMed ID: 35606667
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
Catena L; Bichisao E; Milione M; Valente M; Platania M; Pusceddu S; Ducceschi M; Zilembo N; Formisano B; Bajetta E
Tumori; 2011; 97(5):564-7. PubMed ID: 22158484
[TBL] [Abstract][Full Text] [Related]
11. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015.
Genus TSE; Bouvier C; Wong KF; Srirajaskanthan R; Rous BA; Talbot DC; Valle JW; Khan M; Pearce N; Elshafie M; Reed NS; Morgan E; Deas A; White C; Huws D; Ramage J
Br J Cancer; 2019 Nov; 121(11):966-972. PubMed ID: 31649320
[TBL] [Abstract][Full Text] [Related]
12. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study.
Abdel-Rahman O; Rahbari N; Reissfelder C; Oweira H
Int J Colorectal Dis; 2021 May; 36(5):941-947. PubMed ID: 33145607
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Cohort Study of Histology-Proven Neuroendocrine Neoplasms in the Italian Area of Udine.
Valent F; Tullio A; Kara E; Cipri C; Sciannimanico SM; Vescini F; Grimaldi F
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):448-457. PubMed ID: 32660412
[TBL] [Abstract][Full Text] [Related]
15. Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.
Wang Z; An K; Li R; Liu Q
Front Endocrinol (Lausanne); 2021; 12():801741. PubMed ID: 34987482
[TBL] [Abstract][Full Text] [Related]
16. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
[TBL] [Abstract][Full Text] [Related]
18. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
Boyar Cetinkaya R; Aagnes B; Myklebust TÅ; Thiis-Evensen E
Int J Cancer; 2018 Mar; 142(6):1139-1147. PubMed ID: 29082524
[TBL] [Abstract][Full Text] [Related]
19. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.
Pu N; Habib JR; Bejjani M; Yin H; Nagai M; Chen J; Kinny-Köster B; Chen Q; Zhang J; Yu J; Wu W; Lou W
Ann Transl Med; 2021 Feb; 9(4):329. PubMed ID: 33708956
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study.
Zhang P; Wang W; Lu M; Zeng C; Chen J; Li E; Tan H; Wang W; Yu X; Tang Q; Zhao J; Shen L; Li J
Cancer Med; 2018 Sep; 7(9):4361-4370. PubMed ID: 30062861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
